A National Prospective Cohort of Patients With Idiopathic Nephrotic Syndrome Beginning in Childhood. (PIN'SNP)

Pediatric idiopathic nephrotic syndrome (INS) is a rare disease for which the optimal therapeutic strategy has not yet been defined. A network of clinicians treating complicated forms of this disease (grouped within the Société de Néphrologie Pédiatrique, SNP) exists, but to date there is no prospective cohort following up these patients that would facilitate the development of cohort-nested trials. This absence of structured follow up makes it difficult to set up prospective studies.

The main objective is to create a prospective cohort of pediatric INS patients to collect cases treated in SNP centers, to study their epidemiological characteristics, and to provide a basis for comparison for future cohort-nested trials.

Study Overview

• Status: Recruiting
• Conditions: Idiopathic Nephrotic Syndrome
• Intervention / Treatment: Other: Inclusion and follow up of pediatric patients with an idiopathic nephrotic syndrome,

Detailed Description

In this study, data from patients with INS will be recorded prospectively, regularly and systematically. The cohort will be composed of patients followed by pediatric nephrologists affiliated with the SNP. Metropolitan France, Reunion Island and Mayotte are the geographical areas concerned. It is planned to integrate other French overseas departments and territories, in particular the West Indies.

This is therefore a prospective, multicenter, cohort follow-up study. The data will be centralized via a secure website dedicated to the study.

Data will be obtained from:

• Medical record data (hospitalization/consultations) as part of routine clinical follow-up for patients with active disease. This information will be medically validated and integrated into the database with the help of clinical research staff.
• A telephone interview for annual follow-ups for patients whose absence of active disease no longer requires a systematic medical visit. This structured interview will be administered by telephone by the study's clinical research staff.
• Self-administered or hetero-administered quality of life questionnaires (PEDS-QL), self-administered or hetero-administered treatment compliance questionnaires (Morisky's Score), and questionnaires on the aesthetic impact of treatments (Ferriman's Score). These questionnaires will be centralized and reported to the database by the study's clinical research staff.

• Study Type: Observational
• Enrollment (Estimated): 850

Contacts and Locations

• Study Contact: Name: Vincent Guigonis, MD; Phone Number: +33 5 55 0563 58; Email: vincent.guigonis@unilim.fr
• Study Contact Backup: Name: Claire Bahans, PhD; Phone Number: +33 5 55 05 63 58; Email: claire.bahans@chu-limoges.fr

Study Locations

• France
  • Limoges, France, 87 042
    • Recruiting
    • Limoges hospital
    • Contact: Vincent GUIGONIS, MD; Phone Number: +33 5 55 05 63 58; Email: vincent.guigonis@unilim.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: No older than 18 years (Child, Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Pediatric idiopathic nephrotic syndrome

Description

Inclusion Criteria:

• Patient under 18 years of age
• With idiopathic nephrotic syndrome (according to SPN criteria) beginning after January 1, 2018
• Child seen at least once in consultation or hospitalization by a pediatrician member of the Society of Pediatric Nephrology
• Residing in France
• Consent signed by parents and patient's agreement to participate (if of age)
• Affiliated to a social security system.

Exclusion Criteria:

• Refusal of the patient or legal representatives to participate in the cohort

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Inclusion and follow up of pediatric patients; Inclusion and follow up of pediatric patients with an idiopathic nephrotic syndrome, from the beginning of the disease to 18 years old or transfer of the follow-up to a nephrology unit for adults. 130 new patients are expected to be included on an annual basis.	Other: Inclusion and follow up of pediatric patients with an idiopathic nephrotic syndrome,; The study consists in collecting clinical, biological, psychological and social data of INS pediatric patients. A bio collection is also created: blood, urine, hair and nails will be collected at the beginning of the INS (before starting immunosuppressive treatment).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of cases included in the cohort and description of their characteristics	Number of followed cases, gender, and age; Geographical localization of followed cases; Progressive disease pattern (relapses, corticosteroid dependence, other treatments used); Serious side effects related to treatment	2 years

Collaborators and Investigators

• Sponsor: University Hospital, Limoges
• Investigators: Principal Investigator: Vincent GUIGONIS, MD, University Hospital, Limoges

Study record dates

Study Major Dates

• Study Start (Actual): March 13, 2020
• Primary Completion (Estimated): January 1, 2027
• Study Completion (Estimated): January 1, 2045

Study Registration Dates

• First Submitted: December 17, 2019
• First Submitted That Met QC Criteria: December 17, 2019
• First Posted (Actual): December 23, 2019

Study Record Updates

• Last Update Posted (Actual): August 21, 2023
• Last Update Submitted That Met QC Criteria: August 17, 2023
• Last Verified: July 1, 2023

More Information

Terms related to this study

• Keywords: Cohort - Idiopathic nephrotic syndrome - child
• Additional Relevant MeSH Terms: Pathologic Processes; Kidney Diseases; Urologic Diseases; Disease; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Syndrome; Nephrotic Syndrome; Nephrosis; Nephrosis, Lipoid
• Other Study ID Numbers: 87RI19_0006

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No